Business Wire

Xsolla Founder Shurick Agapitov Releases Once Upon Tomorrow Fortnite Island: A Groundbreaking Immersive Experience That Brings the Novel's Universe to Life

12.12.2024 15:00:00 CET | Business Wire | Press release

Share

High-Octane Parkour Challenges Meet Story-Driven Gameplay in a New Fortnite Creative Map Inspired by Once Upon Tomorrow

Shurick Agapitov, founder of Xsolla and visionary in the gaming industry, proudly announces the Once Upon Tomorrow Fortnite Island release. This immersive Fortnite Creative map transports players into the rich narrative world of his novel. The innovative experience, developed in Unreal Editor for Fortnite (UEFN), masterfully combines high-speed parkour challenges with deep thematic elements from Once Upon Tomorrow, inviting players to test their skills while journeying through a visually captivating landscape that embodies the resilience and adventure of the book’s characters.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212923969/en/

(Graphic: Xsolla)

“Once Upon Tomorrow in Fortnite Creative is our way of expanding the reach and depth of the novel, offering players an interactive journey that challenges both their skills and their understanding of the story’s themes,” said Shurick Agapitov, Founder of Xsolla. “We designed this map to captivate players who crave a good challenge and to immerse them in a world that’s visually rich and deeply inspired by the book. It’s an adventure that leverages UEFN’s technical strengths to elevate storytelling in Fortnite in a way that truly transforms the game experience.”

Designed to push the boundaries of Fortnite Creative, Once Upon Tomorrow offers players a dynamic, narrative-driven parkour adventure set within a meticulously crafted environment inspired by Agapitov’s book and vision. Each course presents a series of agility-based challenges that require players to sprint, leap, and climb with precision and speed, all while immersed in a world filled with visual cues that echo the themes of endurance and discovery central to the book. Agapitov has created an experience beyond traditional parkour maps by weaving gameplay with storytelling, delivering both exhilarating gameplay and a meaningful connection to the novel’s world.

Once Upon Tomorrow is a project within Fortnite Creative, seamlessly blending high-stakes parkour with narrative depth. The map is a testament to what can be achieved using UEFN, offering an engaging and multi-layered experience that appeals to Fortnite’s extensive player base and fans of novel and narrative-rich gaming experiences. Every aspect of the map—from its intense gameplay mechanics to its immersive, atmospheric design—has been crafted to set a new standard in Fortnite Creative.

For more information about Once Upon Tomorrow and its immersive Fortnite Creative experience, please visit xsolla.blog/outf

About Shurick Agapitov

Shurick Agapitov is the visionary founder of Xsolla, a globally recognized leader in video game commerce. Known for his contributions to gaming, Web3, and the metaverse, Agapitov has driven Xsolla to become a vital resource for game developers and publishers worldwide. His dedication to enhancing digital and interactive experiences is reflected in the launch of Once Upon Tomorrow, extending his vision beyond the page to the dynamic world of Fortnite Creative.

About Xsolla

Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world, Xsolla supports leading gaming partners such as Valve, Twitch, Epic Games, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, among others.

For additional information and to learn more, please visit xsolla.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241212923969/en/

null

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 07:00:00 CEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 06:05:00 CEST | Press release

Autonomous launch, recovery, and recharge from military vehicles and fixed installations; Three-drone rotation provides persistent surveillance and real-time targeting data in contested environments Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integrati

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye